Krystal Biotech (KRYS) Capital Expenditures Growth (3y) (2019 - 2026)
Krystal Biotech (KRYS) Capital Expenditures Growth (3y) (2019 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,861.65 Bn | 66,861.36 Bn | - | - |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.72 Bn | - | - |
| 3 | Akari Therapeutics | 1,071.19 Bn | 1,071.19 Bn | - | - |
| 4 | BeOne Medicines | 469.11 Bn | 464.32 Bn | 1.35 Bn | -12.25% |
| 5 | Vertex Pharmaceuticals | 123.03 Bn | 115.78 Bn | 2.59 Bn | 46.88% |
| 6 | Regeneron Pharmaceuticals | 70.13 Bn | 61.37 Bn | 3.31 Bn | 8.97% |
| 7 | Belite Bio | 63.44 Bn | 63.44 Bn | - | - |
| 8 | Argenx Se | 55.97 Bn | 50.78 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.53 Bn | 34.52 Bn | 959.66 Mn | 16.27% |
| 10 | Krystal Biotech | 9.92 Bn | 9.09 Bn | 110.08 Mn | -15.54% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -15.54% |
| Dec 31, 2025 | -45.26% |
| Sep 30, 2025 | 68.32% |
| Jun 30, 2025 | -30.44% |
| Mar 31, 2025 | 784.22% |
| Dec 31, 2024 | 30.40% |
| Sep 30, 2024 | -32.12% |
| Jun 30, 2024 | 23.85% |
| Mar 31, 2024 | -21.60% |
| Dec 31, 2023 | 60.71% |
| Sep 30, 2023 | -57.97% |
| Jun 30, 2023 | -54.90% |
| Mar 31, 2023 | 108.87% |
| Dec 31, 2022 | 256.15% |
| Sep 30, 2022 | -221.21% |
| Jun 30, 2022 | 611.88% |
| Mar 31, 2022 | -26.49% |
| Dec 31, 2021 | -381.13% |
| Sep 30, 2021 | 172.04% |
| Dec 31, 2020 | 134.91% |